Novo Nordisk May Withhold Xultophy From Germany If Price Talks Fail
This article was originally published in The Pink Sheet Daily
Denmark's diabetes specialist says it may decide not to sell Xultophy in Germany if a high-enough price cannot be negotiated there for the new fixed dose combination of insulin degludec and liraglutide for type 2 diabetes.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.